NASD · Healthcare · Biotechnology · Belgium
Lakefront Biotherapeutics NV ADR is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Lakefront Biotherapeutics NV ADR stock.
Undervalued: intrinsic value $141.23 per share, market price $32.28, margin of safety 77.1% (as of 2026-10-30).
Discounting its cash flows at 7.3% (average of 3 methods) values the shares at $141.23; the price of $32.28 is 77% below that value, and 82% of that value comes from beyond year five.
Leak Score: 47/100 on 9 of 12 signals (On Watch).
LKFT is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 7.3% (average of 3 methods) values the shares at $141.23; the price of $32.28 is 77% below that value, and 82% of that value comes from beyond year five.
$141.23 per share (as of the 2026-10-30 close), against a market price of $32.28. That is a margin of safety of 77.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
47 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.